The Cambridge, Mass.-based company’s neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.
The new patient was added at Portland, Ore.’s Oregon Health & Science University. Surgery to implant the scaffold was performed by study investigators Dr. Ahmed Raslan and Dr. Jason Chang approximately 36 hours after the injury occurred.
“We are pleased that the patient is doing well and wish them continued recovery. We have nine patients enrolled and in follow up and, because we now have over 25 Inspire sites open, expect enrollment to increase in the coming months,” CEO Mark Perrin said in a press release.
The company has added 3 new sites to the trial over the past 2 months, at Pittsburgh, Penn.’s Allegheny General Hospital, Boston’s Beth Israel Deaconess Medical Center and at Alberta, Canada’s Foothills Medical Center.
The Cambridge, Mass.-based company said in August that the Inspire trial’s conversion rate for improvement in the American Spinal Injury Assn.’s 50-point lower extremity motor score is 62.5% – more than double the trial’s objective performance criterion of 25% at 6 months.
InVivo said that the trial’s 9th spinal cord injury patient, implanted with its neuro-spinal scaffold last month, is already showing signs of improvement. The device is surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.
The trial’s 9th patient improved from a complete to incomplete spinal cord injury on the AIS scale between the 2nd and 3rd month after implantation; the patient is the 5th of 8 patients in the company’s Inspire study to show an AIS grade improvement, InVivo said.
The post InVivo Therapeutics adds patient to Inspire spinal scaffold trial appeared first on MassDevice.
from MassDevice http://ift.tt/2eLpZM0
Cap comentari:
Publica un comentari a l'entrada